- Home
- ARTV
as 12-18-2024 10:31am EST
Stocks
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 275.7M | IPO Year: | 2024 |
| Target Price: | $21.25 | AVG Volume (30 days): | 45.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.68 - $17.31 | Next Earning Date: | 11-12-2024 |
| Revenue: | $2,601,000 | Revenue Growth: | -43.11% |
| Revenue Growth (this year): | -99.39% | Revenue Growth (next year): | N/A |
Latest ARTIVA BIOTHERAPEUTICS INC News
ARTV Breaking Stock News: Dive into ARTV Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
a month ago
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
GlobeNewswire
2 months ago
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
GlobeNewswire
3 months ago
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
GlobeNewswire
4 months ago
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Simply Wall St.
5 months ago
Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans?
Compare ARTV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARTV ARTIVA BIOTHERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.